相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series
Alessandra Iurlo et al.
HEMATOLOGICAL ONCOLOGY (2021)
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre
Paul Deschamps et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Triple-Negative Essential Thrombocythemia: Clinical-Pathological and Molecular Features. A Single-Center Cohort Study
Daniele Cattaneo et al.
FRONTIERS IN ONCOLOGY (2021)
Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding
Abhishek A. Mangaonkar et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views
Naseema Gangat et al.
LEUKEMIA (2021)
The Prevalence of TET2 Gene Mutations in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms (MPN): A Systematic Review and Meta-Analysis
Yuh Cai Chia et al.
CANCERS (2021)
Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
Giuseppe G. Loscocco et al.
CELLS (2021)
Genetic lesions disrupting calreticulin 3'-untranslated region in JAK2 mutation-negative polycythemia vera
Alberto Quattrocchi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms
Laura Palomo et al.
BLOOD (2020)
Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding
Alicia Veninga et al.
HAEMATOLOGICA (2020)
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
Lasse Kjaer
CANCERS (2020)
Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses
Vibe Skov
CANCERS (2020)
Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses
Pierre-Edouard Debureaux et al.
BLOOD ADVANCES (2020)
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Polycythemia Vera in a Patient With Heterozygous Beta-Thalassemia: Coincidence or Causal Relationship?
Konstantinos Kottas et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2020)
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML
Anna L. Brown et al.
BLOOD ADVANCES (2020)
The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know
Daniel A. Arber
SEMINARS IN HEMATOLOGY (2019)
3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
Natasha Szuber et al.
MAYO CLINIC PROCEEDINGS (2019)
Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms
Fiorella Schischlik et al.
BLOOD (2019)
Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms
Pamela Acha et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis
Alessandra Carobbio et al.
BLOOD ADVANCES (2019)
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui et al.
BLOOD CANCER JOURNAL (2018)
Chronic neutrophilic leukemia: new science and new diagnostic criteria
Natasha Szuber et al.
BLOOD CANCER JOURNAL (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders
N. Maslah et al.
LEUKEMIA (2017)
The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations (vol 30, pg 169, 2016)
Umberto Gianelli et al.
MODERN PATHOLOGY (2017)
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study
Margherita Perricone et al.
ONCOTARGET (2017)
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia
Hans Michael Kvasnicka et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions
Manuel Buscarlet et al.
BLOOD (2017)
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Florian Zink et al.
BLOOD (2017)
Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version
Alessandra Iurlo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria
H. Gisslinger et al.
LEUKEMIA (2016)
Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Rifat Zubair Ahmed et al.
Asian Pacific Journal of Cancer Prevention (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms
Tariq I. Mughal et al.
LEUKEMIA & LYMPHOMA (2016)
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Andrew L. Young et al.
NATURE COMMUNICATIONS (2016)
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia
Min-Gu Kang et al.
ONCOTARGET (2016)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis
Umberto Gianelli et al.
LEUKEMIA RESEARCH (2015)
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Presence of calreticulin mutations in JAK2-negative polycythemia vera
Julien Broseus et al.
BLOOD (2014)
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms
Mario Cazzola et al.
BLOOD (2014)
Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
Umberto Gianelli et al.
MODERN PATHOLOGY (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Epidemiology of MPN: What Do We Know?
L. A. Anderson et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease
Leonardo Boiocchi et al.
MODERN PATHOLOGY (2013)
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
J. V. Jovanovic et al.
LEUKEMIA (2013)
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5-Comment
Juergen Thiele et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
A. Pardanani et al.
LEUKEMIA (2010)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Jerry L. Spivak et al.
BLOOD (2008)
The history of myeloproliferative disorders: before and after Dameshek
A. Tefferi
LEUKEMIA (2008)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi et al.
BLOOD (2007)
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
Massimo Primignani et al.
HEPATOLOGY (2006)
分享论文
